|Bid||248.00 x 1000|
|Ask||260.00 x 1100|
|Day's range||244.43 - 258.07|
|52-week range||208.35 - 526.00|
|Beta (5Y monthly)||0.99|
|PE ratio (TTM)||56.65|
|Earnings date||03 Aug 2022 - 08 Aug 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||358.56|
A European court will decide on July 13 whether U.S. life sciences company Illumina's $8 billion cash-and-stock takeover of Grail should be scrutinised by EU antitrust regulators, people familiar with the matter said on Wednesday. The case coincides with the European Commission seeking to expand its power to examine big companies' acquisitions of start-ups aimed at shutting down nascent rivals, with the focus on tech and pharma deals. The Luxembourg-based General Court, Europe's second-top court, declined to comment on the date of its ruling.
Illumina's (ILMN) first companion diagnostic claim for TSO Comprehensive (EU) will help identify cancer patients with NTRK gene fusions for a genomically matched treatment.
Illumina (ILMN) is working on its goals to strengthen its foothold in the multi-billion gene sequencing market with some highly competitive products in its existing portfolio and pipeline.